Analysis results revealed racial and sex disparities among patients with hypertrophic cardiomyopathy who receive implantable cardioverter-defibrillator (ICD) devices. Among patients hospitalized with ...
Chicago, IL - Only one guideline-defined risk factor for sudden cardiac death (SCD) can be enough to consider patients with hypertrophic cardiomyopathy (HCM) for a primary-prevention implantable ...
High-risk patients with hypertrophic cardiomyopathy would not have been protected from sudden death through the recommendation of an implantable cardioverter defibrillator using the European Society ...
Researchers at Tufts Medical Center report reassuring accuracy predicting which patients with a common genetic heart disease are at the most risk of sudden death and thus most need an implanted device ...
The subcutaneous implantable cardioverter–defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the subcutaneous ICD cannot provide bradycardia and ...
"Appropriately selected patients with NICM have the potential to benefit from primary prevention ICD therapy…Besides consideration of ICD placement, attention to guideline-directed medical therapy and ...
MINNEAPOLIS — Switching candidates for implantable cardioverter-defibrillator (ICD) implantation to a dual-function device that also modulates cardiac contractility was associated with successful ...
(MENAFN- Market Press Release) June 5, 2025 4:21 am - The 7 major hypertrophic cardiomyopathy markets reached a value of US$ 312.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback